We did lose some long time longs on the last rinse cycle. I guess they wanted too much too soon.
All we need is an offer and the pps will go that price. If Roche were to make an offer of $20 per share we would be there.
I grew up when you said the Lords prayer every morning at school. 50 years later the world is fast tracking to Hades. Thanks Coop
I have you on ignore because I thought you were permit the basher. You should change your name. Why would you copy her name anyways?
He is talking about the bashers not being able to post facts so they twist the factual posts longs post. rommell has been here for years. He is not a short.
That's her MO. You know it is 1 woman. permit, setto, hugo, dead, punta, carcass, etc etc. Just imagine what she looks like sitting there in her sweatsuit and slippers. Sorry, I can't go on. It is grossing me out!
Inovio's original phase I, designated HPV-001, treated 18 women who had previously been diagnosed with and surgically treated for high grade cervical intraepithelial neoplasia (CIN 2/3), a premalignant lesion that may lead to cervical cancer, with a three-vaccination regimen of its VGX-3100 therapeutic DNA vaccine delivered with its CELLECTRA® electroporation device. In a longer-term analysis of T cell responses by ELISpot at nine or more months after the initial vaccination ( six months post last vaccination), of 13 initially responding patients, 12 (92%) had maintained significant T cell responses nine to 19 months after their first vaccination. One subject that did not respond early on remained a non-responder. Importantly, the level of T cell responses remained strong.
Inovio then initiated this follow-on study, designated HPV-002, with the intent to assess safety and immune responses following a fourth vaccination. Of the original 18 subjects, 11 T-cell responders and two non-responders were eligible and agreed to participate. All thirteen were injected with a fourth dose of 6 mg of VGX-3100, regardless of the original dose they received (0.6 mg (0.3 mg each of two DNA plasmids), 2.0 mg, or 6.0 mg).
To date, of 8 of 13 patients analyzed, 7 of 8 (87%) patients displayed strong T-cell responses that have persisted for up to over two years. One patient that had a negative T-cell response prior to the fourth vaccination remained negative. Response magnitudes remain high and three subjects are responding to additional antigens (among the four antigens encoded by the vaccine) that they were not previously responding to prior to this fourth vaccination.
Inovio is now recruiting for its Phase II study, which is designed to enroll 148 patients with CIN 2/3 or CIN 3 at approximately 25 study centers in the US, Korea, South Africa, Australia, and Canada. This randomized, placebo-controlled study will assess histopathological response to vaccination as the primary endpoint as well as humoral and cell mediated immune responses to VGX-3100. Cervical samples will be analyzed for evidence of immune responses in the cervix. Subjects will also be monitored for tolerability and safety. See the Phase II clinical trial protocol for HPV-003.